HCP
ROIV icon

Hexagon Capital Partners’s Roivant Sciences ROIV Stock Holding History

Hexagon Capital Partners’s Portfolio ROIV Stock Details ROIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-157
Closed -$1.86K – 1903
2024
Q4 		$1.86K Buy
+157
New +$1.86K ﹤0.01% 1439

Other funds holding ROIV

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
PSC
Patient Square Capital Menlo Park, California $564M AUM 261.3% 1-Year Est. Return

Hexagon Capital Partners's ROIV Position: Q1 2025 in Review

Hexagon Capital Partners sold out of Roivant Sciences (ROIV) in Q1 2025, closing a stake of 157 shares — an estimated $1.86K sold.

Hexagon Capital Partners first reported a position in ROIV in Q4 2024 and held it in 1 quarter. The position peaked at $1.86K in Q4 2024. 312 funds tracked by Wall St. Rank hold ROIV as of Q1 2025.

  • Hexagon Capital Partners reported no remaining Roivant Sciences position as of Q1 2025 after selling out during the quarter.
  • Hexagon Capital Partners sold 157 Roivant Sciences shares in Q1 2025, an estimated $1.86K.
  • Hexagon Capital Partners first reported a position in Roivant Sciences in Q4 2024 and held it in 1 quarter.
  • Hexagon Capital Partners's Roivant Sciences position peaked at $1.86K in Q4 2024.
  • 312 funds tracked by Wall St. Rank held Roivant Sciences as of Q1 2025.

Based on Hexagon Capital Partners's 13F filing for Q1 2025, filed 29 Apr 2025.